ATE485834T1 - Verfahren zum nachweis von bindegewebswachstumsfaktor zur diagnose von nierkrankheiten - Google Patents

Verfahren zum nachweis von bindegewebswachstumsfaktor zur diagnose von nierkrankheiten

Info

Publication number
ATE485834T1
ATE485834T1 AT99948154T AT99948154T ATE485834T1 AT E485834 T1 ATE485834 T1 AT E485834T1 AT 99948154 T AT99948154 T AT 99948154T AT 99948154 T AT99948154 T AT 99948154T AT E485834 T1 ATE485834 T1 AT E485834T1
Authority
AT
Austria
Prior art keywords
growth factor
connective tissue
tissue growth
kidney diseases
diagnosing kidney
Prior art date
Application number
AT99948154T
Other languages
English (en)
Inventor
Bruce Riser
Mark Denichilo
Original Assignee
Ford Henry Health System
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ford Henry Health System, Fibrogen Inc filed Critical Ford Henry Health System
Application granted granted Critical
Publication of ATE485834T1 publication Critical patent/ATE485834T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99948154T 1998-09-08 1999-09-08 Verfahren zum nachweis von bindegewebswachstumsfaktor zur diagnose von nierkrankheiten ATE485834T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9947198P 1998-09-08 1998-09-08
US11285598P 1998-12-16 1998-12-16
PCT/US1999/020601 WO2000013706A1 (en) 1998-09-08 1999-09-08 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor

Publications (1)

Publication Number Publication Date
ATE485834T1 true ATE485834T1 (de) 2010-11-15

Family

ID=26796145

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99948154T ATE485834T1 (de) 1998-09-08 1999-09-08 Verfahren zum nachweis von bindegewebswachstumsfaktor zur diagnose von nierkrankheiten

Country Status (11)

Country Link
US (3) US20040224360A1 (de)
EP (1) EP1112088B1 (de)
JP (1) JP4863548B2 (de)
KR (1) KR20010085767A (de)
CN (1) CN1326361A (de)
AT (1) ATE485834T1 (de)
AU (1) AU6138799A (de)
CA (1) CA2342280A1 (de)
DE (1) DE69942893D1 (de)
HK (1) HK1038318A1 (de)
WO (1) WO2000013706A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1173757B1 (de) * 1999-04-23 2008-08-06 Shiva Biomedical, LLC Diagnostisches verfahren für nierenkrankheiten in menschen
US6933104B1 (en) 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
EP1311277A4 (de) * 2000-07-18 2004-08-25 Joslin Diabetes Center Inc Methoden zur fibrose-modulation
JP4291572B2 (ja) 2001-02-01 2009-07-08 シグマ−アルドリッチ・カンパニー 分子プルダウンおよび免疫沈降用途のための視感度を強化した改善親和性マトリックス
US20030113816A1 (en) 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
JP2006507799A (ja) * 2002-06-04 2006-03-09 メタボレックス インコーポレーティッド 糖尿病およびインスリン抵抗性の診断および治療の方法
US20050233304A1 (en) * 2002-10-11 2005-10-20 Yamanouchi Pharmaceutical Co., Ltd. Method of screening remedy for renal failure
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US8258105B2 (en) 2003-10-07 2012-09-04 Isis Pharmaceuticals, Inc. Antisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
CN1929861B (zh) * 2004-02-11 2010-12-29 法布罗根股份有限公司 Ctgf作为糖尿病肾病的治疗靶点
WO2005077413A1 (en) 2004-02-11 2005-08-25 Fibrogen, Inc. Ctgf as target for the therapy of diabetic nephropathy
US7780949B2 (en) * 2005-01-10 2010-08-24 Rosalind Franklin University Of Medicine And Science Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
AU2006244144A1 (en) * 2005-05-05 2006-11-16 Fibrogen, Inc. Diagnostic marker for diabetic vascular complications
JP2009528820A (ja) * 2006-02-22 2009-08-13 フィロジェン・エッセペア 血管腫瘍マーカー
WO2008046517A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Ctgf as a biomarker, therapeutic and diagnostic target
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
EP2331141B1 (de) 2008-08-25 2016-01-06 Excaliard Pharmaceuticals, Inc. Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
WO2011002525A1 (en) * 2009-07-02 2011-01-06 Fibrogen, Inc. Methods for treatment of muscular dystrophy
CN102947326B (zh) 2010-04-02 2016-02-10 罗莎琳德富兰克林大学医学与科学院 用于治疗用途的ccn3肽以及其类似物
US9114112B2 (en) 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
BR112013019803A2 (pt) 2011-02-02 2019-06-11 Excaliard Pharmaceuticals Inc método de tratar quelóides ou cicatrizes hipertróficas usando os compostos anti-sentido objetivando fator de desenvolvimento de tecido conjuntivo (ctgf)
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
WO2020244540A1 (zh) 2019-06-04 2020-12-10 江苏恒瑞医药股份有限公司 抗结缔组织生长因子抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5753517A (en) * 1996-03-29 1998-05-19 University Of British Columbia Quantitative immunochromatographic assays
US5928888A (en) 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
EP1043335A4 (de) * 1997-12-25 2005-08-31 Japan Tobacco Inc Monoklonaler antikörper gegen den bindegewebewachstumsfaktor sowie dessen medizinische verwendungen
WO2005077413A1 (en) * 2004-02-11 2005-08-25 Fibrogen, Inc. Ctgf as target for the therapy of diabetic nephropathy

Also Published As

Publication number Publication date
DE69942893D1 (de) 2010-12-09
US20090017559A1 (en) 2009-01-15
US8110367B2 (en) 2012-02-07
KR20010085767A (ko) 2001-09-07
US20040224360A1 (en) 2004-11-11
WO2000013706A8 (en) 2000-08-10
JP4863548B2 (ja) 2012-01-25
WO2000013706A9 (en) 2000-09-28
EP1112088A1 (de) 2001-07-04
US20050136502A1 (en) 2005-06-23
EP1112088B1 (de) 2010-10-27
JP2002524422A (ja) 2002-08-06
AU6138799A (en) 2000-03-27
CN1326361A (zh) 2001-12-12
WO2000013706A1 (en) 2000-03-16
CA2342280A1 (en) 2000-03-16
HK1038318A1 (zh) 2002-03-15

Similar Documents

Publication Publication Date Title
ATE485834T1 (de) Verfahren zum nachweis von bindegewebswachstumsfaktor zur diagnose von nierkrankheiten
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
PT914344E (pt) Ensaio e reagentes para a quantificacao de hbnp
ATE420204T1 (de) Verfahren zur detektion von erkrankungen
HK1184534A1 (zh) 通過測定半乳糖苷凝集素- 或者血小板反應蛋白- 的水平鑒定具有發生心力衰竭風險的受試者的方法
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
ATE278186T1 (de) Elektrochemischer sensor zur bestimmung der blutgerinnung, ein entsprechendes blutgerinnungsmesssystem sowie ein verfahren zur bestimmung der blutgerinnung
NO20050186L (no) Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser
ATE438737T1 (de) Verfahren für den nachweis von erkrankungen
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
DE60317422D1 (de) Mediator-stabilisierende Verbindung und Methoden zur Verwendung zur Detektion elektrochemischer Analyte
WO2001057537A3 (en) Methods for diagnosis of alzheimer's disease
DE69808930D1 (de) Leberfunktionstest
DE69939544D1 (de) Verfahren zum nachweis von nierenkrankheiten und zur pathologischen überwachung
EP1162461B8 (de) Automatisches Verfahren zur quantitativen Bestimmung und Überwachung von exogenem Hämoglobin in Vollblut, Blutplasma und Blutserum
ATE314648T1 (de) Diagnostisches verfahren für asthma
ATE302947T1 (de) Verfahren zum nachweis eines lipoprotein- akutphaseprotein-komplexes
DE60038614D1 (de) Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen
FI980748A (fi) Menetelmä luun hajoamisnopeuden määrittämiseksi
DK0587090T3 (da) Fremgangsmåde til bestemmelse af thromboseforårsagende lupus-antikoagulat-antistoffer.
DE69618451D1 (de) Verfahren zur feststellung einer allergie
ATE359519T1 (de) Diagnostisches verfahren für chronische obstruktive lungen krankheit
DE602005023973D1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
DE50305379D1 (de) Lichtquelle für ein messsystem mit photoempfindlicher elektrode zum nachweis eines oder mehrerer analyten
RU93028213A (ru) Способ определения сахара в крови

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties